These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25003571)

  • 1. The use of obinutuzumab in chronic lymphocytic leukemia.
    Wierda W
    Clin Adv Hematol Oncol; 2014 Jun; 12(6):395-7. PubMed ID: 25003571
    [No Abstract]   [Full Text] [Related]  

  • 2. Obinutuzumab (Gazyva) for chronic lymphocytic leukemia.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):e114-5. PubMed ID: 25538980
    [No Abstract]   [Full Text] [Related]  

  • 3. Obinutuzumab for the treatment of chronic lymphocytic leukemia.
    Rogers KA; Jones JA
    Drugs Today (Barc); 2014 Jun; 50(6):407-19. PubMed ID: 24983589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.
    Seiter K; Mamorska-Dyga A
    Clin Interv Aging; 2015; 10():951-61. PubMed ID: 26109852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib: searching for a partner drug.
    Kater AP; Brown JR
    Lancet Oncol; 2019 Jan; 20(1):3-5. PubMed ID: 30522966
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of obinutuzumab in the treatment of chronic lymphocytic leukemia.
    Jean GW; Comeau JM
    Am J Health Syst Pharm; 2015 Jun; 72(11):933-42. PubMed ID: 25987688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia.
    Stephens DM
    Blood; 2019 Nov; 134(20):1691-1696. PubMed ID: 31488409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Visceral leishmaniasis after alemtuzumab in a patient with chronic lymphocytic leukaemia.
    Pitini V; Cascio A; Arrigo C; Altavilla G
    Br J Haematol; 2012 Jan; 156(1):1. PubMed ID: 21790529
    [No Abstract]   [Full Text] [Related]  

  • 9. Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.
    Shah A
    Ann Pharmacother; 2014 Oct; 48(10):1356-61. PubMed ID: 25037849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
    Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Samoilova O; Novak J; Ben-Yehuda D; Strugov V; Gill D; Gribben JG; Hsu E; Lih CJ; Zhou C; Clow F; James DF; Styles L; Flinn IW
    Lancet Oncol; 2019 Jan; 20(1):43-56. PubMed ID: 30522969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obinutuzumab looks impressive in CLL.
    Cancer Discov; 2014 Apr; 4(4):OF5. PubMed ID: 24706674
    [No Abstract]   [Full Text] [Related]  

  • 12. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
    Cramer P; von Tresckow J; Eichhorst B; Hallek M
    Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obinutuzumab for chronic lymphocytic leukemia.
    Rioufol C; Salles G
    Expert Rev Hematol; 2014 Oct; 7(5):533-43. PubMed ID: 25163491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations.
    Reda G; Orofino N; Cassin R; Sciumè M; Fattizzo B; Cortelezzi A
    Expert Opin Drug Saf; 2016 Jun; 15(6):865-73. PubMed ID: 26967902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.
    Cramer P; von Tresckow J; Fink AM; Robrecht S; Giza A; Tausch E; Müller L; Knauf W; Zingerle M; Al-Sawaf O; Langerbeins P; Fischer K; Kreuzer KA; Kneba M; Wendtner CM; Stilgenbauer S; Eichhorst B; Hallek M
    Am J Hematol; 2024 Jun; 99(6):1192-1195. PubMed ID: 38578022
    [No Abstract]   [Full Text] [Related]  

  • 16. Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.
    Langerak AW; Ritgen M; Goede V; Robrecht S; Bahlo J; Fischer K; Steurer M; Trněný M; Mulligan SP; Mey UJM; Trunzer K; Fingerle-Rowson G; Humphrey K; Stilgenbauer S; Böttcher S; Brüggemann M; Hallek M; Kneba M; van Dongen JJM
    Blood; 2019 Jan; 133(5):494-497. PubMed ID: 30455380
    [No Abstract]   [Full Text] [Related]  

  • 17. Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions.
    Freeman CL; Morschhauser F; Sehn L; Dixon M; Houghton R; Lamy T; Fingerle-Rowson G; Wassner-Fritsch E; Gribben JG; Hallek M; Salles G; Cartron G
    Blood; 2015 Dec; 126(24):2646-9. PubMed ID: 26447188
    [No Abstract]   [Full Text] [Related]  

  • 18. High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia.
    Al-Sawaf O; Lilienweiss E; Bahlo J; Robrecht S; Fink AM; Patz M; Tandon M; Jiang Y; Schary W; Ritgen M; Tausch E; Stilgenbauer S; Eichhorst B; Fischer K; Hallek M; Kreuzer KA
    Blood; 2020 Mar; 135(11):866-870. PubMed ID: 31990291
    [No Abstract]   [Full Text] [Related]  

  • 19. Obinutuzumab in chronic lymphocytic leukemia.
    Dupuis J
    Future Oncol; 2015 Sep; 11(18):2503-13. PubMed ID: 26285615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obinutuzumab: a review of its use in patients with chronic lymphocytic leukaemia.
    Hoy SM
    Drugs; 2015 Feb; 75(3):285-96. PubMed ID: 25586272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.